Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Status:
Terminated
Trial end date:
2019-12-20
Target enrollment:
Participant gender:
Summary
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a
human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or
PD-L1). Durvalumab is also known as a checkpoint inhibitor.
This study is evaluating the combination regimen of mocetinostat and durvalumab in
participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.